Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications

References

• Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science244, 359–362 (1989).
   PubMed Web of Science ®Google Scholar
• Cerino A, Mondelli MU. Identification of an immunodominant B cell epitope on the hepatitis C virus nonstructural region defined by human monoclonal antibodies. J. Immunol.147, 2692–2696 (1991).
   Google Scholar
• Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis.20, 17–35 (2000).
   PubMed Web of Science ®Google Scholar
• Jauncey M, Micallef JM, Gilmour S et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J. Infect. Dis.190, 1270–1274 (2004).
   PubMedGoogle Scholar
• Lim JK. Natural history of hepatitis C infection: a concise review. Yale J. Biol. Med.74, 229–237 (2001).
   Google Scholar
• Seeff LB. Natural history of chronic hepatitis C. Hepatology36, S35–S46 (2002).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy R et al. Peg-interferon α-2a plus ribavirin for chronic hepatitis C. N. Engl. J. Med.347, 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon S et al. Peginterferon α-2b plus ribavirin compared to interferon α-2b plus ribavirin for the treatment of chronic hepatitis C: a randomised trial. Lancet358, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral. Hepat.6, 35–47 (1999).
   PubMed Web of Science ®Google Scholar
• Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N. Engl. J. Med.334, 1685–1690 (1996).
   PubMed Web of Science ®Google Scholar
• Tibbs CJ. Methods of transmission of hepatitis C. J. Viral Hepatitis2, 113–119 (1995).
   PubMed Web of Science ®Google Scholar
• Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst. Use Misuse33, 1197–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Wodak A, Crofts N. Once more unto the breach: controlling hepatitis C in injecting drug users. Addiction91, 181–184 (1996).
   PubMed Web of Science ®Google Scholar
• Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology29, 1596–1601 (1999).
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy J-F, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J. Hepatology40, 319–326 (2004).
   PubMedGoogle Scholar
• Law MG. Modelling the hepatitis C virus epidemic in Australia. J. Gastroenterol. Hepatol.14, 1100–1107 (1999).
   PubMedGoogle Scholar
• Law MG, Dore GJ, Bath N et al. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int. J. Epidemiol.32, 717–724 (2003).
   PubMed Web of Science ®Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health90, 1562–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Empirically calibrated model of hepatitis C virus infection in the United States. Am. J. Epidemiol.156, 761–773 (2002).
   PubMed Web of Science ®Google Scholar
• Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl.9, 331–338 (2003).
   PubMed Web of Science ®Google Scholar
• Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can. J. Gastroenterol.14, 575–580 (2000).
   PubMed Web of Science ®Google Scholar
• Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur. J. Gastroenterol. Hepatol.14, 25–34 (2002).
   PubMed Web of Science ®Google Scholar
• Sypsa V, Touloumi G, Tassopoulos NC et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J. Viral. Hepat.11, 366–374 (2004).
   PubMedGoogle Scholar
• Buti M, San Miguel R, Brosa M et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J. Hepatol.42, 639–645 (2005).
   PubMed Web of Science ®Google Scholar
• Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. Hepatology42, 711–723 (2005).
   PubMed Web of Science ®Google Scholar
• Hutchinson SJ, Bird SM, Taylor A, Goldberg DJ. Estimating the prevalence, incidence and cessation of injecting drug use in Glasgow 1960–2000: combining expert opinion with capture-recapture prevalence data. Int. J. Drug Policy17, 29–34 (2006).
   Web of Science ®Google Scholar
• Hutchinson SJ, Bird SM, Taylor A, Goldberg DJ. Modelling the spread of hepatitis C virus infection among injecting drug users in Glasgow: implications for prevention. Int. J. Drug Policy17, 211–221 (2006).
   Web of Science ®Google Scholar
• Alter MJ, Hadler SC, Judson FN et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA264, 2231–2235 (1990).
   PubMed Web of Science ®Google Scholar
• Alter MJ. The epidemiology of acute and chronic hepatitis C. Clin. Liver Dis.1, 559–568 (1997).
   PubMedGoogle Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med.341, 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet349, 825–832 (1997).
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-α2b in patients with histologically mild chronic hepatitis C. Ann. Intern. Med.127, 855–865 (1997).
   PubMed Web of Science ®Google Scholar
• Mattsson I, Weiland O, Glaumann H. Long-term follow-up of chronic post-transfusion non-A, non-B hepatitis: clinical and histological outcome. Liver8, 184–188 (1988).
   PubMedGoogle Scholar
• Tremolada F, Casarin C, Alberti A et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J. Hepatology16, 273–281 (1992).
   PubMed Web of Science ®Google Scholar
• Dore GJ, Freeman AJ, Law M, Kaldor JM. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antiviral Therapy8, 365–372 (2003).
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology34, 809–816 (2001).
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis.33, 562–569 (2001).
   PubMed Web of Science ®Google Scholar
• Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin. Gastroenterol. Hepatol.3, 1150–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J. Viral. Hepat.10, 285–293 (2003).
   PubMed Web of Science ®Google Scholar
• El Saadany S, Coyle D, Giulivi A, Afzal M. Economic burden of hepatitis C in Canada and the potential impact of prevention. Results from a disease model. Eur. J. Health Econom.6, 159–165 (2005).
   PubMedGoogle Scholar
• Siebert U, Sroczynski G, Rossol S et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut52, 425–432 (2003).
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA290, 228–237 (2004).
   Google Scholar
• Annemans L, Warie H, Nechelput M, Peraux B. A health economic model to assess the long-term effects and cost–effectiveness of PEG IFN α-2a in hepatitis C virus infected patients. Acta Gastroenterol. Belg.67, 1–8 (2003).
   Google Scholar
• Grieve R, Roberts J, Wright M et al. Cost–effectiveness of interferon α or peginterferon α with ribavirin for histologically mild chronic hepatitis C. Gut55, 1332–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Sypsa V, Touloumi G, Papatheodoridis GV et al. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J. Viral. Hepat.12, 543–550 (2005).
   Google Scholar
• Dillon JF. What is the best treatment? J. Viral. Hepat.11(Suppl. 1), 23–27 (2004).
   PubMedGoogle Scholar
• Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of interferon α treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology116, 378–386 (1999).
   PubMedGoogle Scholar
• Poynard T, McHutchinson J, Davis GL et al. Impact of interferon and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C. Hepatology32, 1131–1137 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg D, Hutchinson S, Anderson E, Stein K. Screening for hepatitis C virus infection: a prioritised approach. In: Key Advance in the Effective Management of Hepatitis C Infection (2005).
   Google Scholar
• Australian National Council on AIDS and Related Diseases Hepatitis C Sub-Committee. Hepatitis C Virus Projections Working Group: Estimates and Projections of the Hepatitis C Virus Epidemic in Australia. University of New South Wales, Australia (1998).
   Google Scholar